The animal biotech sector reached a landmark in February when the US Food and Drug Administration (FDA) announced the approval of ATryn, an anticoagulant protein derived from the milk of ...

Atryn was rejected because GTC simply did not present enough appropriate data to allay EMEA's concerns about its immunogenicity. GTC has been developing Atryn since 1993 principally for treating ...

The first transgenic drug approved in Europe, ATryn, is recombinant human antithrombin, an anticlotting protein secreted into the milk of transgenic goats developed by GTC Biotherapeutics in ...

The Business Research Company's Atryn Global market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase ...